Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6986093rdf:typepubmed:Citationlld:pubmed
pubmed-article:6986093lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:6986093lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:6986093lifeskim:mentionsumls-concept:C0006982lld:lifeskim
pubmed-article:6986093lifeskim:mentionsumls-concept:C1321905lld:lifeskim
pubmed-article:6986093pubmed:issue1lld:pubmed
pubmed-article:6986093pubmed:dateCreated1980-3-24lld:pubmed
pubmed-article:6986093pubmed:abstractTextMBD has long been considered a childhood disorders. Recent research suggests that in some it persists into adult life and that at least one form is a consequence of reduced activity of dopaminergic systems in the brain. To test this hypothesis, three adults with "presumptive" MBD were given L-dopa plus carbidopa. Although overall this combination was less effective than stimulant medication, all the patients showed an initial response, and in one patient L-dopa seemed to potentiate the effect of methylphenidate. The authors point out that various dopamine agonists have different effects and that the possible potentiation effect is consistent with a dopaminergic hypothesis.lld:pubmed
pubmed-article:6986093pubmed:languageenglld:pubmed
pubmed-article:6986093pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6986093pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6986093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6986093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6986093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6986093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6986093pubmed:statusMEDLINElld:pubmed
pubmed-article:6986093pubmed:monthJanlld:pubmed
pubmed-article:6986093pubmed:issn0002-953Xlld:pubmed
pubmed-article:6986093pubmed:authorpubmed-author:WenderP HPHlld:pubmed
pubmed-article:6986093pubmed:authorpubmed-author:WoodD RDRlld:pubmed
pubmed-article:6986093pubmed:authorpubmed-author:ReimherrF WFWlld:pubmed
pubmed-article:6986093pubmed:issnTypePrintlld:pubmed
pubmed-article:6986093pubmed:volume137lld:pubmed
pubmed-article:6986093pubmed:ownerNLMlld:pubmed
pubmed-article:6986093pubmed:authorsCompleteYlld:pubmed
pubmed-article:6986093pubmed:pagination73-5lld:pubmed
pubmed-article:6986093pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:meshHeadingpubmed-meshheading:6986093-...lld:pubmed
pubmed-article:6986093pubmed:year1980lld:pubmed
pubmed-article:6986093pubmed:articleTitleAn open clinical trial of L-dopa and carbidopa in adults with minimal brain dysfunction.lld:pubmed
pubmed-article:6986093pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6986093pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:6986093pubmed:publicationTypeCase Reportslld:pubmed